沙格列汀联合胰岛素用药在2型糖尿病治疗中的临床作用

Clinical Role of Saxagliptin Combined with Insulin in the Treatment of Type 2 Diabetes Mellitus

目的:探讨沙格列汀联合胰岛素用药在2型糖尿病治疗中的临床作用。方法:共选取100例2型糖尿病患者为研究对象,选自2018年1月-2019年6月,患者按照随机盲选法平分成两组,分别列入到对照组与观察组中,每组50例,其中一组成员采用胰岛素皮下注射治疗,另外一组成员联合采用沙格列汀治疗,对比两组血糖水平(FBG、2 h PG及HbA1c)及胰岛素抵抗指数(HOMA-β及HOMA-IR)。结果:与对照组比较,观察组FBG、2 h PG及HbA1c水平下降幅度更大,血糖控制效果更佳(P<0.05);观察组HOMA-β指数(40.56±6.18),对照组为(30.85±4.49),观察组显著高于对照组(P<0.05);观察组HOMA-IR指数(2.01±0.2),对照组为(2.55±0.35),观察组显著低于对照组(P<0.05)。结论:针对2型糖尿病患者,沙格列汀联合胰岛素用药降糖效果明显,能有效改善胰岛素抵抗指数,有利于疾病预后。

Objective:To investigate the clinical effect of Saxagliptin combined with Insulin in the treatment of type 2 diabetes mellitus(T2DM).Method:A total of 100 patients with type 2 diabetes mellitus were selected as subjects.From January 2018 to June 2019,the patients were randomly divided into two groups,control group(n=50)and observation group(n=50).One group was treated with subcutaneous injection of Insulin and the other group was treated with Saxagliptin.The blood glucose level(FBG,2 h PG and HbA1c),and insulin resistance index(HOMA-βand HOMA-IR)was compared between the two groups.Result:Compared with the control group,the levels of FBG,2 h PG and HbA1c in the observation group decreased more significantly and the effect of blood glucose control was better(P<0.05).The HOMA-βindex in the observation group(40.56±6.18)was significantly higher than(30.85±4.49)in the control group(P<0.05).The HOMA-IR index of the observation group was(2.01±0.22),that of the control group was(2.55±0.35),the observation group was significantly lower than that of the control group(P<0.05).Conclusion:For patients with type 2 diabetes mellitus,Saxagliptin combined with Insulin has obvious hypoglycemic effect.It can effectively improve insulin resistance index and is beneficial to the prognosis of the disease.